orthotopic pdac bearing mice Search Results


orthotopic pdac bearing mice  (Bio X Cell)
93
Bio X Cell orthotopic pdac bearing mice
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Orthotopic Pdac Bearing Mice, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/InVivoMAb+anti-mouse+IL-1+R/bio_rxiv__2025__02__23__639774-126-8-17
Average 93 stars, based on 1 article reviews
orthotopic pdac bearing mice - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
kpc - mixed background  (CancerTools Org)
99
CancerTools Org kpc - mixed background
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Kpc Mixed Background, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/KPC+-+Mixed+Background/custom%40153600%4041005303
Average 99 stars, based on 1 article reviews
kpc - mixed background - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
kpc - c57/bl6 background  (CancerTools Org)
99
CancerTools Org kpc - c57/bl6 background
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Kpc C57/Bl6 Background, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/KPC+-+C57%2FBL6+background/custom%40153474%4041005303
Average 99 stars, based on 1 article reviews
kpc - c57/bl6 background - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
fvb/njnarl female mice  (biolasco taiwan)
90
biolasco taiwan fvb/njnarl female mice
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Fvb/Njnarl Female Mice, supplied by biolasco taiwan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/c57b+6j+mice/pmc09380514__gutjnl___2021___325180supp001-57-2-27
Average 90 stars, based on 1 article reviews
fvb/njnarl female mice - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
female b6 129sf1 j mice  (Jackson Laboratory)
86
Jackson Laboratory female b6 129sf1 j mice
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Female B6 129sf1 J Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/129s7+b6+j+rag1tm1mom/pm30525443__nn8b06164_si_001-93-20-26
Average 86 stars, based on 1 article reviews
female b6 129sf1 j mice - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
c57bl/6 female mice  (biolasco taiwan)
90
biolasco taiwan c57bl/6 female mice
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
C57bl/6 Female Mice, supplied by biolasco taiwan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/balb+c+mice/pmc09380514__gutjnl___2021___325180supp001-57-10-27
Average 90 stars, based on 1 article reviews
c57bl/6 female mice - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
infinium methylationepic arrays  (INFINIUM Inc)
90
INFINIUM Inc infinium methylationepic arrays
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Infinium Methylationepic Arrays, supplied by INFINIUM Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/infinium+humanmethylation450+beadchip/pmc09216338-237-8-22
Average 90 stars, based on 1 article reviews
infinium methylationepic arrays - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cationic nanostructured lipid carriers (nlc) microrna mir-34a and mir-143/145  (NanoVector)
90
NanoVector cationic nanostructured lipid carriers (nlc) microrna mir-34a and mir-143/145
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Cationic Nanostructured Lipid Carriers (Nlc) Microrna Mir 34a And Mir 143/145, supplied by NanoVector, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/mir+143+145+nanovector/pm37765331-388-50-51
Average 90 stars, based on 1 article reviews
cationic nanostructured lipid carriers (nlc) microrna mir-34a and mir-143/145 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
syngeneic immunocompetent c57bl 6 mice  (Jackson Laboratory)
86
Jackson Laboratory syngeneic immunocompetent c57bl 6 mice
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Syngeneic Immunocompetent C57bl 6 Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/c57bl6+immunocompetent/pmc08557351-378-35-39
Average 86 stars, based on 1 article reviews
syngeneic immunocompetent c57bl 6 mice - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
c57bl 6 mice  (Charles River Laboratories)
86
Charles River Laboratories c57bl 6 mice
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
C57bl 6 Mice, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/6+c57bl+mice/bio_rxiv__64898__2025__12__10__693406-193-0-5
Average 86 stars, based on 1 article reviews
c57bl 6 mice - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
c57bl 6j wildtype mice  (Jackson Laboratory)
86
Jackson Laboratory c57bl 6j wildtype mice
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
C57bl 6j Wildtype Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/6j+c57bl+mice+wildtype/bio_rxiv__64898__2026__03__16__711688-238-10-16
Average 86 stars, based on 1 article reviews
c57bl 6j wildtype mice - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
scid/bg mice  (Harlan Winkelmann)
90
Harlan Winkelmann scid/bg mice
Mice bearing 9-day-old <t>orthotopic</t> PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).
Scid/Bg Mice, supplied by Harlan Winkelmann, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/orthotopic+pdac+bearing+mice/balb+c+mice/pm21699694-56-10-25
Average 90 stars, based on 1 article reviews
scid/bg mice - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Mice bearing 9-day-old orthotopic PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).

Journal: bioRxiv

Article Title: IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer

doi: 10.1101/2025.02.23.639774

Figure Lengend Snippet: Mice bearing 9-day-old orthotopic PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with agonistic CD40 antibody or isotype control (200 µg/mouse, intraperitoneal). Bulk transcriptomic analysis of tumors was performed after 2 weeks of treatment initiation (n = 2 mice/group). (A) Volcano plot highlighting differentially expressed genes (DEGs) between CD40-treated and isotype control tumors. (B) Gene Set Enrichment Analysis (GSEA) of bulk RNA-seq data showing hallmark pathways enriched in CD40-treated tumors compared to controls. Upregulated pathways included inflammatory response, IFNγ response, and IL-6/JAK-STAT signaling, while oncogenic pathways such as MYC targets V2, E2F targets, and G2M checkpoint were significantly downregulated (FDR < 0.05). (C) Summary of gene ranks, normalized enrichment scores (NES), p-values, and adjusted p-values (padj) for hallmark pathways. (D) Enrichment plots for select hallmark pathways, illustrating the distribution of pathway-associated genes in the ranked gene list. (E) Heatmap of hallmark gene signatures, depicting relative expression across samples, normalized by row Z-scores. (F) Kaplan-Meier survival curves of orthotopic PDAC-bearing mice treated with CD40 antibody or isotype control (log-rank test, n = 5-6 mice/group).

Article Snippet: Beginning 9 days after tumor implantation, subcutaneous and orthotopic PDAC-bearing mice were treated with anti-IL-1R1 (Clone JAMA-147, BioXCell) or isotype control antibodies (BioXCell) administered intraperitoneally.

Techniques: Imaging, Control, RNA Sequencing, Expressing

Mice bearing 9-day-old orthotopic PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with the indicated antibodies (200 µg/mouse, intraperitoneal). (a) Bulk transcriptomic analysis of orthotopic PDAC tumors after 2 weeks of treatment initiation (*p < 0.05; unpaired t-test, n = 2 mice/group). (b) Kaplan-Meier survival curves (log-rank test, n = 5-6 mice/group). (c) Tumor growth kinetics in subcutaneous PDAC-bearing mice treated every 3 days with agonistic CD40 antibody, anti-IL-1R1 antibody, their combination, or left untreated (****p < 0.0001; two-way ANOVA, n = 5-8 mice/group). (d) Representative H&E-stained tumor sections showing necrosis after 2 weeks of treatment (n = 3-4 mice/group). (e) Quantification of necrotic areas (**p < 0.01; one-way ANOVA, n = 3-4 mice/group). (f) Flow cytometric analysis of PMN-MDSCs in peripheral blood after 2 weeks of treatment (*p < 0.05; unpaired Student’s t-test, n = 5 mice/group). (g) Volcano plot of differentially expressed genes (DEGs) in subcutaneous PDAC tumors treated with anti-IL-1R1 versus untreated controls (red: upregulated; green: downregulated; 546 up, 530 down; p ≤ 0.05, log2FC ≥ 0). (h–i) Gene Ontology (GO) enrichment analysis of DEGs from (g), showing significantly upregulated (h) and downregulated (i) biological processes. (j) Volcano plot of DEGs comparing combination therapy (CD40 + anti-IL-1R1) versus CD40 monotherapy (524 up, 534 down; p ≤ 0.05, log2FC ≥ 0). (k–l) GO enrichment analysis of DEGs from (j), highlighting upregulated (k) and downregulated (l) pathways. (m) Gene Set Enrichment Analysis (GSEA) plots demonstrating the enrichment of indicated gene sets in the combination therapy group compared to CD40 monotherapy.

Journal: bioRxiv

Article Title: IL-1R1 Blockade Enhances CD40 Agonist-Mediated Immune Responses but Fails to Increase Efficacy or Mitigate Hepatotoxicity in Pancreatic Cancer

doi: 10.1101/2025.02.23.639774

Figure Lengend Snippet: Mice bearing 9-day-old orthotopic PDAC tumors (confirmed by luminescence imaging) were treated every 3 days with the indicated antibodies (200 µg/mouse, intraperitoneal). (a) Bulk transcriptomic analysis of orthotopic PDAC tumors after 2 weeks of treatment initiation (*p < 0.05; unpaired t-test, n = 2 mice/group). (b) Kaplan-Meier survival curves (log-rank test, n = 5-6 mice/group). (c) Tumor growth kinetics in subcutaneous PDAC-bearing mice treated every 3 days with agonistic CD40 antibody, anti-IL-1R1 antibody, their combination, or left untreated (****p < 0.0001; two-way ANOVA, n = 5-8 mice/group). (d) Representative H&E-stained tumor sections showing necrosis after 2 weeks of treatment (n = 3-4 mice/group). (e) Quantification of necrotic areas (**p < 0.01; one-way ANOVA, n = 3-4 mice/group). (f) Flow cytometric analysis of PMN-MDSCs in peripheral blood after 2 weeks of treatment (*p < 0.05; unpaired Student’s t-test, n = 5 mice/group). (g) Volcano plot of differentially expressed genes (DEGs) in subcutaneous PDAC tumors treated with anti-IL-1R1 versus untreated controls (red: upregulated; green: downregulated; 546 up, 530 down; p ≤ 0.05, log2FC ≥ 0). (h–i) Gene Ontology (GO) enrichment analysis of DEGs from (g), showing significantly upregulated (h) and downregulated (i) biological processes. (j) Volcano plot of DEGs comparing combination therapy (CD40 + anti-IL-1R1) versus CD40 monotherapy (524 up, 534 down; p ≤ 0.05, log2FC ≥ 0). (k–l) GO enrichment analysis of DEGs from (j), highlighting upregulated (k) and downregulated (l) pathways. (m) Gene Set Enrichment Analysis (GSEA) plots demonstrating the enrichment of indicated gene sets in the combination therapy group compared to CD40 monotherapy.

Article Snippet: Beginning 9 days after tumor implantation, subcutaneous and orthotopic PDAC-bearing mice were treated with anti-IL-1R1 (Clone JAMA-147, BioXCell) or isotype control antibodies (BioXCell) administered intraperitoneally.

Techniques: Imaging, Staining